by Team Small News | Mar 24, 2025 | Glenmark, Pharma
Glenmark Pharma has announced that its US subsidiary, Glenmark Therapeutics Inc., has received approval from the US Food and Drug Administration (USFDA) for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC). This approval allows Glenmark to market the... by Team Small News | Mar 15, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India under the brand name Glempa. The company has introduced three treatment options: Glempa (Empagliflozin 10/25 mg), Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg),... by Team Small News | Mar 14, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals Ltd. has launched its new product range, Glempa, in India. The range consists of Empagliflozin, a widely recognized SGLT2 inhibitor, in three forms: Glempa (Empagliflozin 10/25 mg), Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg), and... by Team Small News | Mar 13, 2025 | Alkem, Glenmark, Mankind, Pharma
The price of the diabetes drug empagliflozin, also known as Jardiance, has been significantly reduced by almost one-tenth in India. The drug, developed by German pharma giant Boehringer Ingelheim, is used to control blood sugar levels in patients with type 2 diabetes.... by Team Small News | Mar 11, 2025 | Glenmark, Pharma
Glenmark Therapeutics Inc., a US-based company, has announced the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful (OTC), a product that is comparable to the active ingredient in MiraLAX Powder for Solution, 17 grams from Bayer HealthCare LLC.... by Team Small News | Mar 9, 2025 | Glenmark, Pharma
Mahavir International’s “Project Vatsalya – Pregnancy to Infancy” has been recognized for its outstanding efforts in eradicating malnutrition among women and children. The initiative received the prestigious Glenmark Nutrition Award 2025, which comes...